相关实验视频

Updated: Jan 12, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

瘦个体中非酒精性脂肪性肝病的新兴表型:有什么不同?

Priyankar Dey¹

¹Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.

Frontiers in endocrinology

|November 5, 2025

概括

瘦非酒精性脂肪肝病 (NAFLD) 或与代谢功能障碍相关的脂肪性肝病 (MASLD) 影响正常体重的成年人,并带有显著的肝脏和死亡风险. 这种情况需要定制的诊断和治疗策略,而不仅仅是以肥胖为重点的方法.

科学领域:

肝病学肝病学是一种肝病学.
代谢障碍代谢障碍代谢障碍
流行病学流行病学

背景情况:

非酒精性脂肪性肝病 (NAFLD),现在代谢功能障碍相关的脂肪性肝病 (MASLD),在正常体重的成年人中是一种与肥胖相关的形式不同的新兴表型.
这种瘦瘦的NAFLD表型带来了显著的代谢和肝脏风险,挑战了当前以肥胖为中心的脂肪肝疾病观点.

研究的目的:

审查和整合全球有关瘦肉性NAFLD流行病学,发病因子,风险因素,自然史和治疗的数据.
阐明NAFLD在正常体重指数 (BMI) 个体中的独特特征和临床影响.

主要方法:

全球流行病学数据,分子调查和临床研究的全面审查.
对文献数据库进行选,以研究瘦肉性NAFLD的流行率,遗传学,代谢概况和长期结果.

主要成果:

瘦身NAFLD影响全球NAFLD人口的5-20%,特别是在亚洲群体 (~45%).
在正常的BMI个体中,特征是内脏肥胖,肉和遗传因素 (PNPLA3,TM6SF2,MBOAT7变异),肠道失调和改变胆酸代谢的贡献.
与肥胖的NAFLD相比,瘦瘦的NAFLD显示出与肥胖的NAFLD相比,所有原因死亡率,晚期纤维化,肝硬化,肝细胞癌和心血管疾病的风险相似或增加,尽管代谢并发症较少.

结论:

瘦肉性NAFLD是一种临床上显著的疾病,需要不同的诊断和治疗方法.
推的干预措施包括适度减肥 (3-5%),饮食改变 (果糖,胆固醇限制) 和抵抗运动.
未来的研究应该专注于标准化分类,非侵入性生物标志物和针对瘦肉NAFLD表型的向疗法.

关键词:

这是一种PNPLA3蛋白.所有原因的死亡率.有纤维化的纤维化.我们的肠道微生物群.瘦弱的NAFLD可以.瘦瘦的纳什 (NASH) 是一个.这种类型的麻症是sarcopenia.内脏脂肪的脂肪性是什么

更多相关视频

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

相关概念视频

Liver Physiology

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...